1
|
Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management. J Clin Med 2021; 10:jcm10163760. [PMID: 34442055 PMCID: PMC8397216 DOI: 10.3390/jcm10163760] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 08/13/2021] [Accepted: 08/18/2021] [Indexed: 12/11/2022] Open
Abstract
A family history of melanoma greatly increases the risk of developing cutaneous melanoma, a highly aggressive skin cancer whose incidence has been steadily increasing worldwide. Familial melanomas account for about 10% of all malignant melanomas and display an inheritance pattern consistent with the presence of pathogenic germline mutations, among which those involving CDKN2A are the best characterized. In recent years, a growing number of genes, such as MC1R, MITF, CDK4, POT1, TERT, ACD, TERF2IP, and BAP1, have been implicated in familial melanoma. The fact that individuals harboring these germline mutations along with their close blood relatives have a higher risk of developing multiple primary melanomas as well as other internal organ malignancies, especially pancreatic cancer, makes cascade genetic testing and surveillance of these families of the utmost importance. Unfortunately, due to a polygenic inheritance mechanism involving multiple low-risk alleles, genetic modifiers, and environmental factors, it is still very difficult to predict the presence of these mutations. It is, however, known that germline mutation carriers can sometimes develop specific clinical traits, such as high atypical nevus counts and specific dermoscopic features, which could theoretically help clinicians predict the presence of these mutations in prone families. In this review, we provide a comprehensive overview of the high- and intermediate-penetrance genes primarily linked to familial melanoma, highlighting their most frequently associated non-cutaneous malignancies and clinical/dermoscopic phenotypes.
Collapse
|
2
|
Buljan M, Marušić Z, Franceschi N. Dermoscopy of BAP1-inactivated melanocytic tumours. Australas J Dermatol 2021; 63:86-90. [PMID: 34398452 DOI: 10.1111/ajd.13689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Revised: 07/19/2021] [Accepted: 07/24/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Marija Buljan
- Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.,School of Dental Medicine, University of Zagreb, Zagreb, Croatia
| | - Zlatko Marušić
- Clinical Department of Pathology and Cytology, University Hospital Center Zagreb, Zagreb, Croatia
| | - Nika Franceschi
- Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
| |
Collapse
|
3
|
Soares de Sá BC, de Macedo MP, Torrezan GT, Braga JCT, Fidalgo F, Moredo LF, Lellis R, Duprat JP, Carraro DM. BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy. BMC Cancer 2019; 19:1077. [PMID: 31706282 PMCID: PMC6842488 DOI: 10.1186/s12885-019-6226-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Accepted: 10/09/2019] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND BRCA1 associated-protein 1 (BAP1) tumor predisposition syndrome is associated with an increased risk for malignant mesotheliomas, uveal and cutaneous melanomas, renal cell carcinomas, and singular cutaneous lesions. The latter are referred to as BAP1-inactivated melanocytic tumors (BIMTs). When multiple BIMTs manifest, they are considered potential markers of germline BAP1 mutations. CASE PRESENTATION Here, we report a novel pathogenic BAP1 germline variant in a family with a history of BIMTs, cutaneous melanomas, and mesotheliomas. We also describe singular pathological aspects of the patient's BIMT lesions and their correlation with dermoscopic and reflectance confocal microscopy findings. CONCLUSIONS This knowledge is crucial for the recognition of BIMTs by dermatologists and pathologists, allowing the determination of appropriate management for high-risk patients, such as genetic investigations and screening for potentially aggressive tumors.
Collapse
Affiliation(s)
- Bianca Costa Soares de Sá
- Skin Cancer Department, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - Mariana Petaccia de Macedo
- Department of Pathology, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - Giovana Tardin Torrezan
- Laboratory of Genomics and Molecular Biology, A.C. Camargo Cancer Center, Rua Taguá, 440, São Paulo, SP CEP: 0508-010 Brazil
- National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, , Rua Taguá, 400, São Paulo, SP CEP: 01509-900 Brazil
| | - Juliana Casagrande Tavoloni Braga
- Skin Cancer Department, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - Felipe Fidalgo
- Laboratory of Genomics and Molecular Biology, A.C. Camargo Cancer Center, Rua Taguá, 440, São Paulo, SP CEP: 0508-010 Brazil
| | - Luciana Facure Moredo
- Skin Cancer Department, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - Rute Lellis
- Department of Pathology, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - João Pereira Duprat
- Skin Cancer Department, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, São Paulo, SP CEP: 01509-900 Brazil
| | - Dirce Maria Carraro
- Laboratory of Genomics and Molecular Biology, A.C. Camargo Cancer Center, Rua Taguá, 440, São Paulo, SP CEP: 0508-010 Brazil
- National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, A.C. Camargo Cancer Center, Rua Professor Antonio Prudente, 211 Liberdade, , Rua Taguá, 400, São Paulo, SP CEP: 01509-900 Brazil
| |
Collapse
|
4
|
Yélamos O, Navarrete-Dechent C, Marchetti MA, Rogers T, Apalla Z, Bahadoran P, Blázquez-Sánchez N, Busam K, Carrera C, Dusza SW, de la Fouchardière A, Ferrara G, Gerami P, Kittler H, Lallas A, Malvehy J, Millán-Cayetano JF, Nelson KC, Quan VL, Puig S, Stevens H, Thomas L, Marghoob AA. Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society. J Am Acad Dermatol 2018; 80:1585-1593. [PMID: 30244062 DOI: 10.1016/j.jaad.2018.09.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 08/23/2018] [Accepted: 09/06/2018] [Indexed: 11/24/2022]
Abstract
BACKGROUND Multiple BRCA1-associated protein 1 (BAP1)-inactivated melanocytic tumors (BIMTs) have been associated with a familial cancer syndrome involving germline mutations in BAP1. OBJECTIVES We sought to describe the clinical and dermoscopic features of BIMTs. METHODS This was a retrospective, multicenter, case-control study. Participating centers contributed clinical data, dermoscopic images, and histopathologic data of biopsy-proven BIMTs. We compared the dermoscopic features between BIMTs and control patients. RESULTS The dataset consisted of 48 BIMTs from 31 patients (22 women; median age 37 years) and 80 control patients. Eleven patients had a BAP1 germline mutation. Clinically, most BIMTs presented as pink, dome-shaped papules (n = 24). Dermoscopically, we identified 5 patterns: structureless pink-to-tan with irregular eccentric dots/globules (n = 14, 29.8%); structureless pink-to-tan with peripheral vessels (n = 10, 21.3%); structureless pink-to-tan (n = 7, 14.9%); a network with raised, structureless, pink-to-tan areas (n = 7, 14.9%); and globular pattern (n = 4, 8.5%). The structureless with eccentric dots/globules pattern and network with raised structureless areas pattern were only identified in BIMT and were more common in patients with BAP1 germline mutations (P < .0001 and P = .001, respectively). LIMITATIONS Limitations included our small sample size, retrospective design, the absence of germline genetic testing in all patients, and inclusion bias toward more atypical-looking BIMTs. CONCLUSIONS Dome-shaped papules with pink-to-tan structureless areas and peripheral irregular dots/globules or network should raise the clinical suspicion for BIMT.
Collapse
Affiliation(s)
- Oriol Yélamos
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
| | - Cristián Navarrete-Dechent
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Michael A Marchetti
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Tova Rogers
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Zoe Apalla
- First Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - Philippe Bahadoran
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | - Klaus Busam
- Pathology Department, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Cristina Carrera
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain
| | - Stephen W Dusza
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Gerardo Ferrara
- Anatomic Pathology Unit, Hospital of Macerata, Macerata, Italy
| | - Pedram Gerami
- Dermatology Department, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Harald Kittler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Aimilios Lallas
- First Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - Josep Malvehy
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain
| | | | - Kelly C Nelson
- Dermatology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Victor Li Quan
- Dermatology Department, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Susana Puig
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain
| | | | - Luc Thomas
- Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud and Lyon's Cancer Research Center INSERM U1052 - CNRS UMR5286, Lyon, France
| | - Ashfaq A Marghoob
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|